KẾT QUẢ ĐIỀU TRỊ BEVACIZUMAB KẾT HỢP HOÁ TRỊ TRONG UNG THƯ BUỒNG TRỨNG GIAI ĐOẠN MUỘN

Abstract

Background: The objective of this study was to assess the the efficacy and safety of bevacizumab with chemotherapy in platinum-sensitive recurrent and stage IV ovarian cancer. Patients and methods: The study was designed as a retrospective and prospective study, in which 30 patients with platinum-sensitive recurrent or stage IV ovarian carcinoma who were treated with at least 3 cycles of bevacizumab and chemotherapy at K Hospital from 1/2019 to 6/2022. We assessed clinical characteristics, treatment response, survival, and toxicity. Results: The mean age was 53.8±9.76. The high-grade serous adenocarcinoma accounted for 73.3%. The disease control rate was high (86.7%), there were 3 (10%) patients with complete response, 12 patients (40%) with partial response, accounting, the overall response rate was 50%. Median progression-free survival (PFS) was 17.7 months and was independent of surgical status at relapse, age group or combination chemotherapy regimen (p>0.05). The rates of neutropenia grade 3.4 was low. Grade 1,2 hypertension was noted in 4 patients and no grade 3 or higher hypertension was reported. One patient experienced GI perforation and had to discontinue the treatment. Conclusions: The addition of bevacizumab to standard chemotherapy was proven efficacy and safety in patients with platinum-sensitive recurrent and stage IV ovarian cancer.